KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

Mariano Provencio, Mark M Awad, Jonathan D Spicer, Annelies Janssens, Fedor Moiseyenko, Yang Gao, Yasutaka Watanabe, Aurelia Alexandru, Florian Guisier, Nikolaj Frost, Fabio Franke, T Jeroen Nicolaas Hiltermann, Jie He, Fumihiro Tanaka, Shun Lu, Cinthya Coronado Erdmann, Padma Sathyanarayana, Phuong Tran, Vipul Devas, Tina Cascone

Nat Cancer 7(1) 169-181

PMID41507539
PMCIDPMC12858404
DOI10.1038/s43018-025-01104-z
发表日期2026-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Individuals with non-small-cell lung cancer (NSCLC) with metastases to the ipsilateral mediastinum or subcarinal lymph nodes (N2 disease) have poor long-term survival. This exploratory analysis from the randomized phase 3 CheckMate 77T study assessed clinical outcomes by nodal status in individuals with stage III NSCLC who received neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab (nivolumab) versus neoadjuvant chemotherapy followed by surgery and adjuvant placebo (placebo). Here we show that among patients with N2 disease, nivolumab versus placebo improved event-free survival (1-year rate, 70% versus 45%; hazard ratio, 0.46 (95% confidence interval, 0.30-0.70)) and pathological complete response rate (22.0% versus 5.6%); 77% versus 73% had definitive surgery, of whom 84% versus 74% received a simple lobectomy. Furthermore, nivolumab improved outcomes versus placebo in patients with multistation N2 NSCLC (1-year event-free survival rate: 71% versus 46%; hazard ratio, 0.43 (0.21-0.88); pathological complete response rate, 29.0% versus 2.7%). In the N2 subgroup with definitive surgery, 67% and 59% of patients had nodal downstaging after surgery (57% versus 44% downstaged to node-negative disease). Median EFS in randomized patients with stage III non-N2 NSCLC was not reached with nivolumab and 17.0 months with placebo (1-year EFS rate, 74% versus 62%; hazard ratio, 0.60 (0.33-1.08)). No new safety signals were identified. These findings support perioperative nivolumab plus neoadjuvant chemotherapy as an efficacious treatment for stage III N2 disease and suggest that N2 status may not predict poor prognosis in resectable NSCLC treated with perioperative immunotherapy. ClinicalTrials.gov identifier: NCT04025879 .

KM 提取结果

7 个 Figure · 30 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 3

Fig. 3. EFS in patients with stage III NSCLC by N2 or non-N2 status. a – d , EFS from randomization in patients with N2 NSCLC ( a ), randomization in patients with non-N2 NSCLC ( b ), definitive surgery in patients with N2 NSCLC ( c ) and definitive surgery in patients with non-N2 NSCLC ( d ). Superscript letters ‘a’–‘d’ indicate the following 95% CIs: a, 58–78; b, 34–55; c, 60–84; d, 48–74. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan–Meier estimates on the EFS curve for each randomized arm. Source data

A

EFS from randomization

Fig. 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

EFS from randomization

Fig. 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

EFS from surgery

Fig. 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

EFS from surgery

Fig. 3 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure4 个面板

Fig. 4

Fig. 4. EFS from definitive surgery in patients with stage III N2 or non-N2 NSCLC by pCR status. a – d , EFS from surgery in patients with N2 NSCLC by pCR status ( a ), patients with non-N2 NSCLC by pCR status ( b ), patients with N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( c ) and patients with non-N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( d ). The superscript letter ‘a’ indicates that EFS from surgery included only patients with definitive surgery and with pCR status available. The ‘Without pCR’ subgroup included patients with pCR negatively assessed. The superscript letter ‘b’ indicates that HRs were not calculated for subgroups with less than ten responders in either treatment arm. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate; NC, not calculated. Source data

A

EFS

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

EFS

Fig. 4 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal曲线 3:extreme upward reversal
查看结果
C

EFS

Fig. 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
D

EFS

Fig. 4 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:extreme upward reversal
查看结果
KM Figure4 个面板

Fig. 5

Fig. 5. EFS from randomization in patients with stage III N2 or non-N2 NSCLC by number of adjuvant treatment doses. a – d , EFS from randomization in patients with N2 NSCLC with six or fewer doses of adjuvant treatment ( a ), patients with N2 NSCLC with more than six doses of adjuvant treatment ( b ), patients with non-N2 NSCLC with six or fewer doses of adjuvant treatment ( c ) and patients with non-N2 NSCLC with more than six doses of adjuvant treatment ( d ). The superscript letter ‘a’ indicates that HRs were not calculated for subgroups with less than ten patients with events. Superscript letters ‘b’ and ‘c’ indicate the following 95% CIs: b, 44–89; c, 10–59. Superscript letter ‘d’ indicates that in the nivolumab arm, 28 patients received the maximum 13 doses of adjuvant treatment, and 13 patients received 7–12 doses; in the placebo arm, 23 patients received 13 doses of adjuvant treatment and 18 patients received 7–12 doses. Superscript letters ‘e’–‘h’ indicate the following 95% CIs: e, 79–98; f, 57–84; g, 33–98; h, NR–NR. Superscript letter ‘i’ indicates that in the nivolumab arm, 22 patients received the maximum 13 doses of adjuvant treatment, and 4 patients received 7–12 doses; in the placebo arm, 24 patients received 13 doses of adjuvant treatment, and 9 patients received 7–12 doses. Superscript letters ‘j’ and ‘k’ indicate the following 95% CIs: j, 73–98; k, 74–97. The HRs and two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan–Meier estimates on the EFS curve for each randomized arm. Source data

A

EFS

Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

EFS

Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

EFS

Fig. 5 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

EFS

Fig. 5 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Extended Data Fig. 3

Extended Data Fig. 3. EFS in patients with stage III N2 NSCLC by N2 station. EFS from ( a ) randomization in patients with single-station N2 NSCLC, ( b ) randomization in patients with multi-station N2 NSCLC, ( c ) definitive surgery in patients with single-station N2 NSCLC, and ( d ) definitive surgery in patients with multi-station N2 NSCLC. a The N2 subcategory was not reported in 1 patient in the nivolumab arm. b–e 95% CI: b 54–79; c 30–58; d 50–84; e 28–62. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NR, not reached; NSCLC, non-small cell lung cancer. Source data

A

EFS from randomization

Extended Data Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
B

EFS from randomization

Extended Data Fig. 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

EFS from surgery

Extended Data Fig. 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
D

EFS from surgery

Extended Data Fig. 3 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure6 个面板

Extended Data Fig. 4

Extended Data Fig. 4. EFS in patients with stage III N2 and non-N2 NSCLC with or without pCR. EFS from ( a ) randomization in patients with N2 NSCLC, ( b ) randomization in patients with non-N2 NSCLC, ( c ) randomization in patients with single-station N2 NSCLC, ( d ) randomization in patients with multi-station N2 NSCLC, ( e ) definitive surgery in patients with single-station N2 NSCLC, and ( f ) definitive surgery in patients with multi-station N2 NSCLC. a EFS from randomization included all randomized patients. The “Without pCR” subgroup included patients with pCR negatively assessed, patients without definitive surgery, and patients with definitive surgery but without pCR status available. b HRs were NC for subgroups with <10 responders in either treatment arm. c–j 95% CI: c 100–100; d 100–100; e 47–71; f 30–52; g 100–100; h 57–99; i 50–80; j 45–72. k The N2 subcategory was not reported in 1 patient in the nivolumab arm. l–s 95% CI: l 100–100; m 100–100; n 45–73; o 24–53; p 100–100; q 100–100; r 32–76; s 27–60. t EFS from surgery included only patients with definitive surgery and with pCR status available. The “Without pCR” subgroup included patients with pCR negatively assessed. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer; pCR, pathological complete response. Source data

A

EFS from randomization

Extended Data Fig. 4 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
B

EFS from randomization

Extended Data Fig. 4 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

EFS from randomization

Extended Data Fig. 4 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:flat topline artifact曲线 3:extreme upward reversal
查看结果
D

EFS from randomization

Extended Data Fig. 4 · Panel D

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel D 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:extreme upward reversal
查看结果
E

EFS from surgery

Extended Data Fig. 4 · Panel E

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel E 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact曲线 2:extreme jump曲线 2:extreme upward reversal曲线 3:extreme jump
查看结果
F

EFS from surgery

Extended Data Fig. 4 · Panel F

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel F 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:extreme upward reversal
查看结果
KM Figure4 个面板

Extended Data Fig. 5

Extended Data Fig. 5. EFS in patients with stage III N2 or non-N2 NSCLC by adjuvant treatment status. EFS from randomization in ( a ) patients with N2 NSCLC with at least one dose of adjuvant treatment, ( b ) patients with non-N2 NSCLC with at least one dose of adjuvant treatment, ( c ) patients with N2 NSCLC without adjuvant treatment, and ( d ) patients with non-N2 NSCLC without adjuvant treatment. a,b 95% CI: a 76–94; b 50–75. c HRs were NC for subgroups with <10 patients with events. d–i 95% CI: d 74–97; e 63–89; f 30–84; g NR–NR; h 21–81; i 5–75. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer. Source data

A

EFS

Extended Data Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

EFS

Extended Data Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

EFS

Extended Data Fig. 5 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

EFS

Extended Data Fig. 5 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
KM Figure4 个面板

Extended Data Fig. 6

Extended Data Fig. 6. EFS from definitive surgery in patients with stage III N2 or non-N2 NSCLC by number of adjuvant treatment doses. EFS from surgery in ( a ) patients with N2 NSCLC with ≤6 doses of adjuvant treatment, ( b ) patients with N2 NSCLC with >6 doses of adjuvant treatment, ( c ) patients with non-N2 NSCLC with ≤6 doses of adjuvant treatment, and ( d ) patients with non-N2 NSCLC with >6 doses of adjuvant treatment. a HRs were NC for subgroups with <10 responders in either treatment arm. b In the nivolumab arm, 28 patients received the maximum 13 doses of adjuvant treatment and 13 patients received 7–12 doses; in the placebo arm, 23 patients received 13 doses of adjuvant treatment and 18 patients received 7–12 doses. c In the nivolumab arm, 22 patients received the maximum 13 doses of adjuvant treatment and 4 patients received 7–12 doses; in the placebo arm, 24 patients received 13 doses of adjuvant treatment and 9 patients received 7–12 doses. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer. Source data

A

EFS from surgery

Extended Data Fig. 6 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

EFS from surgery

Extended Data Fig. 6 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

EFS from surgery

Extended Data Fig. 6 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

EFS from surgery

Extended Data Fig. 6 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CheckMate 77T nodal status analysis population. Patients were enrolled between November 2019 and April 2022 and had a median follow-up of 25.4 months (range, 15.7–44.2) as of the 6 September 2023 database lock for this analysis. The denominators used to calculate percentages were based on the number of patients in each previous cohort. The superscript ‘a’ indicates that the enrollment of patients with stage III N3 NSCLC was considered a protocol deviation. Source data
非 KM Figure
Fig. 2Fig. 2. pCR in patients with stage III NSCLC. a , b , pCR in patients with stage III NSCLC by N2 or non-N2 status ( a ) or single-station or multistation N2 status ( b ). The superscript letters (‘a’–‘l’) indicate the following 95% CIs: a, 6.5–26.5; b, 14.0–31.9; c, 1.8–12.5; d, 8.1–33.3; e, 18.4–40.6; f, 2.5–16.8; g, 6.9–33.5; h, 14.7–39.0; i, 1.1–14.6; j, 8.3–39.6; k, 18.2–46.6; l, 1.4–18.3. The superscript ‘m’ indicates that the N2 subcategory was not reported in one patient in the nivolumab arm. Superscript letters ‘n’–‘y’ indicate the following 95% CIs: n, −1.9 to 23.7; o, 9.7–30.9; p, 2.1–18.2; q, −3.6 to 29.3; r, 12.9–39.5; s, 3.0–25.4; t, 9.3–44.0; u, 14.2–48.0; v, 0.1–14.2; w, 12.7–54.0; x, 18.8–59.4; y, 0.1–17.8. The 95% CIs were determined for each treatment arm using the Clopper–Pearson method. An estimate of the unstratified difference in pCR rates and the corresponding 95% CIs were calculated using the Newcombe method. Source data
非 KM Figure
Fig. 6Fig. 6. Change in N stage from baseline to postdefinitive surgery in patients with stage III NSCLC and definitive surgery. Among randomized patients with stage III NSCLC, 115 in the nivolumab arm and 111 in the placebo arm had received definitive surgery. The percentages in individual ribbons represent patients within each baseline N stage group (left) who had the indicated postsurgical N stage (right) among all patients with definitive surgery in that treatment arm. The superscript letter ‘a’ indicates that one (1%) patient in the nivolumab arm with unknown nodal stage at baseline was excluded, and postsurgical N stage was missing for three (3%) additional patients (one with cN1 at baseline and two with cN0 (no regional lymph node involvement by clinical assessment) at baseline). The superscript letter ‘b’ indicates that one (1%) patient in the placebo arm with not reported or cNX stage at baseline was excluded, and postsurgical N stage was missing for four (4%) additional patients (three with cN2 at baseline and one with cN0 at baseline). Source data
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Treatment and surgery summary in patients with stage III N2 and non-N2 NSCLC. Neoadjuvant treatment, surgery, and adjuvant treatment by treatment arm and N2 status in all randomized patients. The denominators used to calculate percentages were based on patients in each N2 or non-N2 subgroup. a One patient in the nivolumab N2 subgroup, 1 patient in the nivolumab non-N2 subgroup, 2 patients in the placebo N2 subgroup, and 1 patient in the placebo non-N2 subgroup did not undergo definitive surgery but did receive adjuvant treatment. AE, adverse event. Source data
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. MPR in patients with stage III N2 and non-N2 NSCLC. Patients with ( a ) N2 or non-N2 NSCLC and ( b ) single-station or multi-station N2 status. a–l 95% CI: a 6.9–29.8; b 20.5–40.2; c 5.5–19.5; d 8.5–36.9; e 27.2–51.0; f 7.5–26.1; g 13.2–44.1; h 28.7–55.9; i 5.1–23.7; j 16.2–51.5; k 35.8–66.3; l 6.5–29.5. m The N2 subcategory was not reported in 1 patient in the nivolumab arm. n − 2.0–26.1; o 13.6–36.6; p 4.3–23.0; q − 4.0–31.8; r 18.2–46.6; s 6.2–32.0; t 10.3–49.6; u 24.5–60.9; v 3.0–25.4; w 15.0–60.1; x 32.8–74.4; y 3.9–31.7. The 95% CIs were determined for each treatment arm using the Clopper-Pearson method. An estimate of the unstratified difference in MPR rates and the corresponding 95% CI were calculated using the Newcombe method. CI, confidence interval; MPR, major pathological response; NSCLC, non-small cell lung cancer. Source data
非 KM Figure
Extended Data Fig. 7Extended Data Fig. 7. Change in T stage from baseline to post-definitive surgery in patients with stage III N2 and non-N2 NSCLC and definitive surgery. Patients with ( a ) stage III N2 NSCLC and definitive surgery or ( b ) non-N2 NSCLC and definitive surgery. Among randomized patients with stage III N2 NSCLC, 70 in the nivolumab arm and 66 in the placebo arm had received definitive surgery. Among randomized patients with stage III N2 NSCLC, 45 in each arm had received definitive surgery. Percentages in individual ribbons represent patients within each baseline T stage group ( left ) who had the indicated post-surgical T stage ( right ) among all patients with definitive surgery in that treatment arm and N2 status subgroup. a One (2%) patient with N2 NSCLC in the placebo arm with not reported or cTX stage at baseline was excluded. b Post-surgical T stage was missing for 3 (7%) patients with non-N2 NSCLC in the nivolumab arm. c One (1%) patient with non-N2 NSCLC in the placebo arm with not reported or cTX stage at baseline was excluded, and post-surgical T stage was missing for 1 (2%) additional patient with cT4 at baseline. Source data
非 KM Figure